Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vistusertib (AZD2014)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

mTOR inhibitor, mTORC2 inhibitor

Related drugs:

‹

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

›

RICTOR amplification	Gastric Cancer	RICTOR amplification	Gastric Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
RICTOR amplification	Small Cell Lung Cancer	RICTOR amplification	Small Cell Lung Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3
FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	FGFR1 mutation	Squamous Cell Carcinoma of Head and Neck	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D	ABSK091 + AZD2014 Sensitive: D – Preclinical ABSK091 + AZD2014 Sensitive : D